Immuron Ltd
IMRN evidence brief
What we can confirm
- Market Cap:
- $11.3M
What it means
What to watch
Prepared research question
What matters most for IMRN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IMRN
Immuron Ltd is an Australian biopharmaceutical company developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory and infectious diseases, with two clinical-stage candidates and a marketed product in Australia.
Key risk: Accumulated deficit
Market Cap
$11.3M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 1 clinical trial for Immuron Ltd.
Immuron Ltd is an Australian biopharmaceutical company developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory and infectious diseases, with two clinical-stage candidates and a marketed product in Australia.
- Immuron is an Australian biopharmaceutical company focused on orally delivered targeted polyclonal antibodies for inflammatory and infectious diseases [sec · filed 2026-09-24].
- The company markets Travelan® and ProIBS® in Australia as listed medicines on the Australian Register for Therapeutic Goods [sec · filed 2026-09-24].
- As of June 30, 2026, Immuron's accumulated deficit was A$84,970,154 [sec · filed 2026-09-24].
- Lead clinical candidates include IMM-124E for Traveler's Diarrhea and IMM-529 for C. difficile infection [sec · filed 2026-09-24].
- The company relies on a single manufacturer for each of its lead compounds, IMM-124E and IMM-529 [sec · filed 2026-09-24].
What works
- Immuron has a proprietary platform for orally delivered targeted polyclonal antibodies that can target viruses or bacteria and neutralize toxins at mucosal surfaces [sec · filed 2026-09-24].
- The company already has a commercial product, Travelan®, listed on the Australian Register for Therapeutic Goods, generating some revenue [sec · filed 2026-09-24].
- Immuron expects its current cash and cash equivalents to fund capital requirements for at least 12 months from the issuance date of its financial statements [sec · filed 2026-09-24].
What to weigh
- Immuron has incurred operating losses and may continue to do so; as of June 30, 2026, its accumulated deficit was A$84,970,154 [sec · filed 2026-09-24].
- The company depends on a single manufacturer for each of its lead compounds, which could cause significant delays or costs if a replacement is needed [sec · filed 2026-09-24].
- Clinical trials are expensive and time-consuming with uncertain outcomes, and positive preclinical results may not translate to clinical success [sec · filed 2026-09-24].
- No prescription product candidates utilizing Immuron's hyper-immune colostrum technology have been approved for commercial sale [sec · filed 2026-09-24].
From the filings
Quoted directly from source documents.
Immuron's accumulated deficit as of June 30, 2026
“As of June 30, 2026, our accumulated deficit was A$84,970,154.”
SEC filings · September 24, 2026
Dependence on single manufacturers for lead compounds
“We currently depend upon a single manufacturer of each of our lead compound IMM-124E and our second clinical asset, IMM-529, and on a sole manufacturer to produce finished drug products”
SEC filings · September 24, 2026
Commercial products marketed in Australia
“We currently market our flagship commercial product Travelan ® and ProIBS ® in Australia, where both products are listed medicines on the Australian Register for Therapeutic Goods.”
SEC filings · September 24, 2026
Risk of never achieving profitability
“We may never be able to achieve or maintain profitability.”
SEC filings · September 24, 2026
Risks & what to watch (4)›
Key risks
- Accumulated deficit — Accumulated deficit of A$84,970,154 as of June 30, 2026; company may continue incurring losses [sec · filed 2026-09-24].
- Single-source manufacturing — Relies on single manufacturers for IMM-124E and IMM-529; replacement could cause significant costs and delays [sec · filed 2026-09-24].
- Clinical trial uncertainty — Clinical trials are expensive, time-consuming, and outcomes are uncertain; positive preclinical results may not predict success [sec · filed 2026-09-24].
- Unproven platform for prescriptions — No prescription product candidates using hyper-immune colostrum technology have been approved for commercial sale [sec · filed 2026-09-24].
What to watch
- Progress and results of clinical trials for IMM-124E (Traveler's Diarrhea) and IMM-529 (C. difficile) [sec · filed 2026-09-24].
- Ability to secure additional funding or partnerships given accumulated deficit and ongoing operating losses [sec · filed 2026-09-24].
- Revenue growth from commercial products Travelan® and ProIBS® in Australia [sec · filed 2026-09-24].
- Any changes in single-source manufacturing dependencies or development of alternative suppliers [sec · filed 2026-09-24].
Sources: SEC filings · Generated September 25, 2026 · How we verify sources →
Run Immuron Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Immuron Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 0.2%
- Days to cover
- 0.6
- Shares short
- 11,600
- Daily short volume (Oct 9, 2026)
- 55.1%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IMRN short interestFrequently asked questions
What is the AI investment thesis for Immuron Ltd?
Immuron Ltd is an Australian biopharmaceutical company developing and commercializing orally delivered targeted polyclonal antibodies for inflammatory and infectious diseases, with two clinical-stage candidates and a marketed product in Australia.
Who is the CEO of Immuron Ltd?
Mr. Steven George Lydeamore CPA, M.B.A. is the chief executive officer of Immuron Ltd (IMRN).
Where is Immuron Ltd headquartered?
Immuron Ltd (IMRN) is headquartered in Carlton, VIC, Australia.
What therapeutic areas does Immuron Ltd focus on?
Immuron Ltd develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.